npj Imaging - Kidney tumoroid characterisation by spatial mass spectrometry with same-section multiplex immunofluorescence uncovers tumour microenvironment lipid signatures associated with...

HGSCs are comprised of multiple cell types, including epithelial cancer cells, mesenchymal cancer cells, carcinoma-associated MSCs, microvascular endothelial cells, and macrophages, each of which supports tumor cells in different contexts14,46,47. The mesenchymal subtype signature is strongly expressed by the fibroblasts...

This study investigates the metabolic vulnerabilities of glioblastoma (GBM), an aggressive brain tumor. Research demonstrates that iron chelation therapy, in combination with standard chemotherapy, significantly enhances the efficacy of treatment against resistant GBM cells in a 3D tumoroid model. Abstract Chemoresistance poses a significant clinical challenge in managing glioblastoma (GBM), limiting the long-term success of traditional treatments. Here, a 3D tumoroid model is used to investigate the metabolic sensitivity of temozolomide (TMZ)-resistant GBM cells to iron chelation by deferoxamine (DFO) and deferiprone (DFP). This work shows that TMZ-resistant GBM cells acquire stem-like characteristics, higher intracellular iron levels, higher expression of aconitase, and elevated reliance on oxidative phosphorylation and proteins associated with iron metabolism. Using a microphysiological model of GBM-on-a-chip consisting of extracellular matrix (ECM)-incorporated tumoroids, this work demonstrates that the combination of iron chelators with TMZ induces a synergistic effect on an in vitro tumoroid model of newly diagnosed and recurrent chemo-resistant patient-derived GBM and reduced their size and invasion. Investigating downstream metabolic variations reveal reduced intracellular iron, increased reactive oxygen species (ROS), upregulated hypoxia-inducible factor-1α, reduced viability, increased autophagy, upregulated ribonucleotide reductase (RRM2), arrested proliferation, and induced cell death in normoxic TMZ-resistant cells. Hypoxic cells, while showing similar results, display reduced responses to iron deficiency, less blebbing, and an induced autophagic flux, suggesting an adaptive mechanism associated with hypoxia. These findings show that co-treatment with iron chelators and TMZ induces a synergistic effect, making this combination a promising GBM therapy.

The ability of DNA origami to penetrate through spheroid tissue and to induce cell death via the extrinsic apoptosis pathway is examined. Both structure of the DNA origami and the attachment of the a...

You have to enable JavaScript in your browser's settings in order to use the eReader.

Here, we present a protocol for engineering biomimetic tumoroid models by plastic compression using centrifugation. We describe steps for generating multi-compartment tumor-stroma models by mixing cells into a collagen hydrogel crosslinked at 37°C and centrifuging the hydrogel. We then detail procedures for generating compartmentalized models and encapsulating the final layered hydrogel containing a 96-well tumor mass in a 24-well stroma. This protocol increases collagen density and improves mec...

Discovery Life Sciences is set to introduce innovative Tumoroid Cell Lines designed to advance oncology research at the Precision Med Tri-Con 2025 event in San Diego.

Discovery Life Sciences is launching Tumoroid Cell Lines at Precision Med Tri-Con 2025 in San Diego to enhance oncology research and therapy development.

Long non-coding RNAs (lncRNAs) have emerged as crucial regulators of cellular processes, overturning

Long non-coding RNAs (lncRNAs) have emerged as crucial regulators of cellular processes, overturning

Real-time secretion analysis from single tumoroids is enabled by a label-free spectroscopic imaging platform with an advanced optofluidic nanoplasmonic biosensor. Demonstrated with colorectal tumoroids to investigate their vascular endothelial growth factor secretion, growth, and movement under various conditions, this platform shows its capability of monitoring secretion dynamics, motility, and morphology and promises new avenues for potential screening applications. Abstract Organoid tumor models have emerged as a powerful tool in the fields of biology and medicine as such 3D structures grown from tumor cells recapitulate better tumor characteristics, making these tumoroids unique for personalized cancer research. Assessment of their functional behavior, particularly protein secretion, is of significant importance to provide comprehensive insights. Here, a label-free spectroscopic imaging platform is presented with advanced integrated optofluidic nanoplasmonic biosensor that enables real-time secretion analysis from single tumoroids. A novel two-layer microwell design isolates tumoroids, preventing signal interference, and the microarray configuration allows concurrent analysis of multiple tumoroids. The dual imaging capability combining time-lapse plasmonic spectroscopy and bright-field microscopy facilitates simultaneous observation of secretion dynamics, motility, and morphology. The integrated biosensor is demonstrated with colorectal tumoroids derived from both cell lines and patient samples to investigate their vascular endothelial growth factor A (VEGF-A) secretion, growth, and movement under various conditions, including normoxia, hypoxia, and drug treatment. This platform, by offering a label-free approach with nanophotonics to monitor tumoroids, can pave the way for new applications in fundamental biological studies, drug screening, and the development of therapies.